These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8725181)

  • 21. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment.
    Matsumura M; Monden T; Nakatani Y; Shimizu H; Domeki N; Yanagi K; Ikeda S; Kawagoe Y; Kasai K
    Med Princ Pract; 2010; 19(1):68-72. PubMed ID: 19996623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia.
    Dayspring T; Qu Y; Keech C
    Metabolism; 2006 Jul; 55(7):972-9. PubMed ID: 16784972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
    Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.
    Neven P; Quail D; Marin F; Creatsas G; Depypere H; Rechberger T; Liu-Léage S; Pavo I; Schmitt H; Nickelsen T
    Maturitas; 2005 Oct; 52(2):87-101. PubMed ID: 15967604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM; Riggs BL; Atkinson EJ; Khosla S
    J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
    Insull W; Davidson MH; Kulkarni PM; Siddhanti S; Ciaccia AV; Keech CA
    Metabolism; 2005 Jul; 54(7):939-46. PubMed ID: 15988705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of D-003 (10 mg/day) on biochemical parameters of bone remodelling in postmenopausal women: a randomized, double-blind study.
    Ceballos A; Mas R; Castaño G; Fernández L; Mendoza S; Menéndez R; González JJ; Illnait J; Gámez R; Mesa M; Fernández J
    Int J Clin Pharmacol Res; 2005; 25(4):175-86. PubMed ID: 16402634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ; de Valk-de Roo GW; Gooren LJ; Netelenbos C
    Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats.
    Bowman AR; Sass DA; Marshall I; Ma YF; Liang H; Jee WS; Epstein S
    J Bone Miner Res; 1996 Aug; 11(8):1191-8. PubMed ID: 8854256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
    Tsai KS; Yen ML; Pan HA; Wu MH; Cheng WC; Hsu SH; Yen BL; Huang KE
    Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.